CD5-targeted CAR-T cells therapy(Senlang Biotechnology)

N/A

Report date: 2026/05/08 20:02:52

Base Information

Drug NameCD5-targeted CAR-T cells therapy(Senlang Biotechnology)
Drug Alias NameNanobody-Based Anti-CD5 CAR-T cells therapy(Senlang Biotechnology)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT-cell surface glycoprotein CD5 modulatorsT lymphocyte replacements
TargetsT-cell surface glycoprotein CD5
Therapy Area/IndicationsLymphoma, T-Cell, PeripheralLymphoma, T-CellPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHebei Senlang Biological Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHebei Senlang Biological Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, T-Cell, PeripheralLymphoma, T-CellPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A